LYMPHIR (denileukin diftitox-cxdl)
INTERLEUKIN 2 · CUTANEOUS T-CELL LYMPHOMA
CITIUS PHARMACE
Drug class
Denileukin Diftitox
Denileukin diftitox is a specific active drug substance rather than an independent therapeutic drug class; the FDA officially classifies it as an interleukin-2 (IL-2) receptor-directed or CD25-directed cytotoxin. Read more about Denileukin Diftitox
1 drugs in this class 1 manufacturers
Drugs in Denileukin Diftitox
Filter & compare in the drug finder →
Opens the drug finder with Denileukin Diftitox preselected. Add indication or manufacturer filters there.
Denileukin diftitox is a specific active drug substance rather than an independent therapeutic drug class; the FDA officially classifies it as an interleukin-2 (IL-2) receptor-directed or CD25-directed cytotoxin.
It is an engineered recombinant fusion protein combining human interleukin-2 with cytotoxic fragments of diphtheria toxin.
This biologic agent selectively binds to cells expressing the IL-2 receptor, undergoes receptor-mediated endocytosis, and delivers the enzymatic toxin domain to inhibit cellular protein synthesis and induce apoptotic cell death.
Clinically, it is indicated for the treatment of hematologic malignancies that express CD25, most notably relapsed or refractory cutaneous T-cell lymphoma.
-
fda.gov
Denileukin diftitox is a specific active drug substance rather than an independent therapeutic drug class; the FDA officially classifies it as an interleukin-2 (IL-2) receptor-directed or CD25-directed cytotoxin It is an engineered recombinant fusion protein combining human interleukin-2 with cytotoxic fragments of diphtheria toxin
-
fda.gov
Denileukin diftitox is a specific active drug substance rather than an independent therapeutic drug class; the FDA officially classifies it as an interleukin-2 (IL-2) receptor-directed or CD25-directed cytotoxin
-
fda.gov
It is an engineered recombinant fusion protein combining human interleukin-2 with cytotoxic fragments of diphtheria toxin
-
fda.gov
This biologic agent selectively binds to cells expressing the IL-2 receptor, undergoes receptor-mediated endocytosis, and delivers the enzymatic toxin domain to inhibit cellular protein synthesis and induce apoptotic cell death
-
cancer.gov
This biologic agent selectively binds to cells expressing the IL-2 receptor, undergoes receptor-mediated endocytosis, and delivers the enzymatic toxin domain to inhibit cellular protein synthesis and induce apoptotic cell death
-
fda.gov
Clinically, it is indicated for the treatment of hematologic malignancies that express CD25, most notably relapsed or refractory cutaneous T-cell lymphoma
-
fda.gov
Clinically, it is indicated for the treatment of hematologic malignancies that express CD25, most notably relapsed or refractory cutaneous T-cell lymphoma
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.